Practical aspects of weekly docetaxel administration schedules

Oncologist

Volumn 9, Issue 5, 2004, Pages 538-545

  Hainsworth, John D ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Administration; Docetaxel; Side effect management; Taxanes; Weekly

Indexed keywords

ARTIFICIAL TEAR; DEXAMETHASONE; DOCETAXEL; STEROID;

ALOPECIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST TUMOR; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; CONJUNCTIVITIS; COUGHING; CUSHING DISEASE; DACRYOCYSTORHINOSTOMY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EPIPHORA; FATIGUE; HAIR LOSS; HUMAN; HYPERGLYCEMIA; LACRIMAL DUCT OCCLUSION; LACRIMATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOSIS; NAIL DISEASE; NEUTROPENIA; ONYCHOLYSIS; ONYCHOMELANOSIS; OPPORTUNISTIC INFECTION; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOLID TUMOR;

AGE FACTORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FATIGUE; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASMS; NEUTROPENIA; PALLIATIVE CARE; TAXOIDS;

EID: 4944221510     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-5-538     Document Type: Review

References (42)

1. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-2354.
2. Martin M, Pienkowski T, Mackey J et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;82(suppl 1):43a.
3. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-2362.
4. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
5. Berry W, Dakhil S, Gregurich MA et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001;28(suppl 15):8-15.
6. Beer TM, Pierce WC, Lowe BA et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12:1273-1279.
7. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26(suppl 17):14-18.
8. Friedland D, Cohen J, Miller R Jr et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999;26(suppl 17):19-23.
9. Climent MA, Tabernero J, Albanell J et al. Preliminary results of a phase II randomized trial of docetaxel (taxotere) as a single agent chemotherapy (CT) administered weekly or 3-weekly in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002;21:52a.
10. Sedky L, El-Dine IS, Hashem B et al. Weekly docetaxel vs every 3-week in advanced breast cancer: results of a pilot comparative study. Proc Am Soc Clin Oncol 2002;21:50b.
11. Camps C, Massuti B, Jimenez AM et al. Second-line docetaxel administered every 3 weeks versus weekly in advanced non-small cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial. Proc Am Soc Clin Oncol 2003;22:625.
12. Gridelli C, Illiano A, Salvagni S et al. Effect on quality-of-life (QoL) of weekly vs 3-weekly docetaxel (D) in second-line treatment of advanced non-small-cell lung cancer: the DISTAL randomized phase 3 study. Proc Am Soc Clin Oncol 2003;22:625.
13. Tomiak E, Piccart MJ, Kerger J et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994;12:1458-1467.
14. Hainsworth JD, Burris HA 3rd, Erland JB et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168.
15. Briasoulis E, Karavasilis V, Anastasopoulos D et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999;10:701-706.
16. Kouroussis C, Agelaki S, Mavroudis D et al. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2000:46:488-492.
17. Stemmler J, Mair W, Stauch M et al. Weekly docetaxel with or without corticosteroid premedication as first or second-line treatment in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002;21:58a.
18. Jackisch C, Eibach H, Knuthet A et al. Phase-II trial of docetaxel weekly as dose dense treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000;19:108a. Updated based on poster presentation.
19. Loeffler TM, Droege C, Hausamen TU. Dose-dense weekly docetaxel (Taxotere®) in metastatic breast cancer. Breast Cancer Res Treat 1999;57:125.
20. Comandone A, Bergnolo P, Donadioet M et al. Phase II trial of weekly docetaxel (D) in heavily pretreated advanced breast cancer (ABC) patients. Proc Am Soc Clin Oncol 2001;20:56b.
21. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002;13:286-292.
22. Hainsworth JD, Burris HA 3rd, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19:3500-3505.
23. Stemmler HJ, Gutschow K, Sommer H et al. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 2001;12:1393-1398.
24. Ramos A, Gonzalez-Ageitos A, Vicente J. Weekly docetaxel (D) for metastatic breast cancer (MBC) progressing after anthracycline treatment. Proc Am Soc Clin Oncol 2000;19:115a. Updated based on poster presentation.
25. Rittershaus A, Lück HJ, Scholz U et al. Weekly docetaxel in pretreated patients with metastatic breast cancer. Breast Cancer Res Treat 1999;57:126.
26. Luck JH, Scholz U, Kühnle H. Weekly taxanes in treatment of metastatic breast cancer. Cancer Invest 2000;18(suppl 1):1-2.
27. Fornasiero A, Daniele O, Ghiotto C et al. Weekly docetaxel for metastatic breast cancer (MBC): a phase II trial. Breast Cancer Res Treat 1999;57:127.
28. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
29. Nistico C, D'Ottavio AM, Vaccaro A et al. Weekly chemotherapy schedule in advanced breast cancer (ABC) patients: ten-year experience at the Regina Elena Cancer Institute. Proc Am Soc Clin Oncol 2000;19:119a.
30. Climent MA, Ruiz A, Llombart-Cussac A et al. Weekly docetaxel in patients with advanced malignancies: toxicity profile and activity results. Proc Am Soc Clin Oncol 1999;18:119a.
31. Petrioli R, Pozzessere D, Messinese S et al. Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy. Oncology 2003;64:300-305.
32. Oh WK, George DJ, Kaufman DS et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 2001;28(suppl 15):40-44.
33. Hainsworth JD, Burns HA 3rd, Litchy S et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Cancer 2000;89:328-333.
34. Serke M, Argiropulos D, Schoenfeld N et al. Second-line therapy with weekly docetaxel in resistant or relapsed non-small cell lung cancer (NSCLC): final results. Proc Am Soc Clin Oncol 2001;20:272b.
35. Garcia-Lopez JL, Domine M, Garrido P et al. Early phase II of docetaxel in second line of advanced non small cell lung cancer (NSCLC): preliminary results. Proc Am Soc Clin Oncol 2000;19:537a.
36. Valerio MR, Russo A, Latteri MA et al. Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study. Lung Cancer 2001;34(suppl 4):S31-S35.
37. Lilenbaum RC, Schwartz MA, Seigel L et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 2001;92:2158-2163.
38. Gomez RG, Perez-Segura P, Mendez M et al. A phase II study of weekly docetaxel in previously treated patients with non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:267b.
39. Petrioli R, Pozzessere D, Messinese S et al. Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer 2003;39:85-89.
40. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999;17:1413-1424.
41. Berry WR, Beer TM. Weekly docetaxel in the elderly: outcomes in mean with androgen independent prostate cancer (AIPC) ≥70 vs <70 years of age. Proc Am Soc Clin Oncol 2003;22:745.
42. Esmaeli B, Hortobagyi G,Esteva F et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002;13:218-221.